Pfizer C. Difficile Vaccine Candidate Misses Main Study Endpoint

By Colin Kellaher


Pfizer Inc. on Tuesday reported mixed results from a Phase 3 study of PF-06425090, its vaccine candidate for the prevention of C. difficile infection, or CDI.

The New... | March 1, 2022

Related Keywords

New York ,United States ,Colin Kellaher ,Pfizer ,Pfizer Inc ,Dow Jones ,Nc Stock Exchange ,News ,Information ,Press Release ,Y ,Colin ,Kellaher ,N ,Tuesday ,Eported ,Ixed ,Results ,Rom ,Hase , ,Study ,F ,Its ,Vaccine ,Candidate ,Or ,The ,Prevention ,Difficile ,Dr ,He Pfe Us7170811035 ,